Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

Also called NCT01327014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 116 participants (enrolled count) (from the registry)
Sponsor
Beijing Peking University WBL Biotech Co., Ltd. (from the registry)
Registry
  • NCT NCT01327014
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01327014. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Drug)
XueZhiKang (XZK), a botanic product with multiple components
Intervention (Drug)
Placebo
Lead sponsor
Beijing Peking University WBL Biotech Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01327014
Content hash
f3caea5a872d934c7be298d6a45b0d11eabdff941457a74f76c5ed89198e7646